Eligo is developing phage-derived drugs (Eligobiotics) to shape the microbiome composition or modulate its function.
Eligo’s research projects are advancing rapidly towards the clinic and require careful evaluation and development of a specific formulation adapted to Eligobiotics.

We are looking for excellent scientists with a strong background in formulation, excited to tackle the ambitious challenges of ensuring phages and phage-derived particles can be delivered to particular microbiome sites of the human body.

If you are creative, curious, and ambitious, with an impeccable work ethic, a strong team spirit, and a desire to have a direct impact in a rapidly-developing field that aims to save lives THIS MISSION IS FOR YOU! Join our rapidly growing of 35 international Eligonauts!

Eligo is a five year old biotech startup spun off from MIT and Rockefeller University, that has been selected by the World Economic Forum as one of the 30 most innovative companies in the world.